Investigator's Choice Chemotherapy
Sponsors
Celldex Therapeutics, Amgen, Genmab, Taizhou Hanzhong biomedical co. LTD, Qilu Pharmaceutical Co., Ltd.
Conditions
Breast CancerDiffuse Large B-Cell LymphomaDiffuse Large B-cell LymphomaHigh-risk Diffuse Large B-Cell LymphomaMetastatic Colorectal CancerTriple-Negative Breast Cancer (TNBC)
Phase 2
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
CompletedNCT01156753
Start: 2010-07-31End: 2012-11-30Updated: 2017-07-02
Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
CompletedNCT03023878
Start: 2017-03-13End: 2019-10-28Updated: 2020-09-14
Phase 3
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Active, not recruitingNCT04628494
Start: 2021-01-13End: 2028-04-01Updated: 2026-03-03
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Not yet recruitingNCT05652894
Start: 2022-12-20End: 2028-10-20Target: 190Updated: 2022-12-15
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
RecruitingNCT06732323
Start: 2025-09-04End: 2028-07-31Target: 504Updated: 2025-09-23
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Active, not recruitingNCT07226752
Start: 2022-10-08End: 2028-06-14Updated: 2026-03-03